Any current/future new fundraising through debt or equity?

There is no specific mention of any new fundraising through debt or equity in the provided transcript. The company expects only a marginal reduction in net debt for FY '24, around 10%, indicating no major debt raising plans. Funds generated will be balanced between debt reduction and capital allocation for growth, suggesting prudent capital management without new large-scale fundraising. The focus is on improving cash flows and preserving funds to support growth initiatives rather than increasing debt. Overall, the discussions point towards managing existing debt and capital efficiently rather

Any current/future capex/capital investment/strategic investment?

Maintenance Capex: Expected to be around INR 70-80 crores per year for compliance across plants. Growth Capex: Most growth investments for the Vizag facility are already made; current focus is on better capacity utilization rather than new capex. Vizag Facility: Qualification of customers ongoing, with substantial capacity utilization improvement expected from H2 FY '24; Q4 FY '24 capacity utilization targeted over 60%. Funds Allocation: Net debt reduction planned to be marginal (~10%) as generated funds will be balanced between debt reduction and capital growth. Strategic Focus: Continued inv

Future growth expectations in sales/revenue/volumes?

Growth in top line for FY '24 and FY '25 is expected to be similar to or better than FY '23 (14% growth in FY '23). Revenue and EBITDA are anticipated to improve year-on-year in FY '24. Major revenue growth is expected from enhanced capacity utilization at the Vizag facility, particularly in the second half of FY '24. New product filings and approvals will contribute to commercial revenues starting in the second half of FY '25. Focus on expanding product mix with quality R&D filings and commercialization over 2-3 years supports sustained growth. CRAMS business is expected to see significant gr

Future growth expectations in earnings/operating earnings/profits/EPS?

The company expects growth in top line and EBITDA in FY '24 and FY '25 to be in line with or better than FY '23 performance. FY '23 saw a 14% revenue growth and a 63% increase in reported EBITDA, with a margin of 15.5%. EBITDA margin is anticipated to improve gradually, targeting the "high teens" and aiming to return to historical levels around 20% by FY '25. Growth drivers include ramping up capacity utilization at the Vizag facility (expected >60% in Q4 FY '24), expanding the product mix, new product launches, and CRAMS business growth (significant margins expected FY '25/FY '26). St

Current/ Expected Orderbook/ Pending Orders?

The company has started receiving orders, indicating active demand. Substantial jump in requirement is expected in the next financial year. Current orders are primarily from the Pondy facility. Vizag facility is being qualified as an additional site to handle orders. There are 11 new pending approvals from the Cuddalore site, which once cleared will trigger new product orders. New products filed from Vizag are expected to enter validation and commercialization phases in 2 to 3 years. Overall, order momentum is expected to increase with enhanced capacity utilization and new product filings.

Solara ActiveQ4 FY23Pharmaceuticals & Biotechnology

Solara Active Q4 FY23 Earnings Call Analysis

Revenue, margin, capex, fundraise and order book outlook from management commentary.

Price: ₹655.25P/E: 67.2Market Cap: ₹3.2K CrSector: Pharmaceuticals & Biotechnology

Management growth scorecard

Revenue

Category 3

Margin

Category 1

Fundraise

N/A

Order

N/A

Capex

Yes

2 of 3 growth signals are positive.

Full analysis

Revenue guidance

Category 3

Growth in top line for FY '24 and FY '25 is expected to be similar to or better than FY '23 (14% growth in FY '23).
Revenue and EBITDA are anticipated to improve year-on-year in FY '24.
Major revenue growth is expected from enhanced capacity utilization at the Vizag facility, particularly in the second half of FY '24.
New product filings and approvals will contribute to commercial revenues starting in the second half of FY '25.
Focus on expanding product mix with quality R&D filings and commercialization over 2-3 years supports sustained growth.
CRAMS business is expected to see significant growth in FY '25 and FY '26, contributing higher gross margins.
Overall, the company aims to return to historical growth levels and improve both revenue and profitability through execution of key strategic focus areas.

Margin guidance

Category 1

The company expects growth in top line and EBITDA in FY '24 and FY '25 to be in line with or better than FY '23 performance.
FY '23 saw a 14% revenue growth and a 63% increase in reported EBITDA, with a margin of 15.5%.
EBITDA margin is anticipated to improve gradually, targeting the "high teens" and aiming to return to historical levels around 20% by FY '25.
Growth drivers include ramping up capacity utilization at the Vizag facility (expected >60% in Q4 FY '24), expanding the product mix, new product launches, and CRAMS business growth (significant margins expected FY '25/FY '26).
Strategic focus areas are growing existing business, new products, cost improvement, backward integration, and enhanced capacity utilization.
Management remains confident about sustainable earnings growth and margin improvement over the medium term.

See what Solara Active management said on margin guidance — free account, 30 seconds.

Fundraise plans

There is no specific mention of any new fundraising through debt or equity in the provided transcript.
The company expects only a marginal reduction in net debt for FY '24, around 10%, indicating no major debt raising plans.
Funds generated will be balanced between debt reduction and capital allocation for growth, suggesting prudent capital management without new large-scale fundraising.
The focus is on improving cash flows and preserving funds to support growth initiatives rather than increasing debt.
Overall, the discussions point towards managing existing debt and capital efficiently rather than pursuing new debt or equity fundraising in the near term.

Order book

The company has started receiving orders, indicating active demand.
Substantial jump in requirement is expected in the next financial year.
Current orders are primarily from the Pondy facility.
Vizag facility is being qualified as an additional site to handle orders.
There are 11 new pending approvals from the Cuddalore site, which once cleared will trigger new product orders.
New products filed from Vizag are expected to enter validation and commercialization phases in 2 to 3 years.
Overall, order momentum is expected to increase with enhanced capacity utilization and new product filings.

See what Solara Active management said on order book — free account, 30 seconds.

Capex plans

Yes

Maintenance Capex: Expected to be around INR 70-80 crores per year for compliance across plants.
Growth Capex: Most growth investments for the Vizag facility are already made; current focus is on better capacity utilization rather than new capex.
Vizag Facility: Qualification of customers ongoing, with substantial capacity utilization improvement expected from H2 FY '24; Q4 FY '24 capacity utilization targeted over 60%.
Funds Allocation: Net debt reduction planned to be marginal (~10%) as generated funds will be balanced between debt reduction and capital growth.
Strategic Focus: Continued investment in R&D for new product filings and CRAMS business expansion, aiming for improved product mix and sustainable growth.
Overall, capex is largely completed with emphasis on optimizing existing assets and incremental maintenance spend.

Track Solara Active — get its next earnings analysis in your feed

How does Solara Active rank vs peers in Pharmaceuticals & Biotechnology?

Pro feature

ThisSolara Active

Rev 3Mar 1

See where Solara Active sits in Pharmaceuticals & BiotechnologySee which companies these are, and every other name in the sector.Open rankings

How does Solara Active rank in Pharmaceuticals & Biotechnology?

Compare Solara Active against every Pharmaceuticals & Biotechnology company (Q4 FY23) on revenue, margins and earnings-call signals.

View Pharmaceuticals & Biotechnology leaderboard →

What Solara Active's management said in earlier quarters

Others in Pharmaceuticals & Biotechnology this season

Lincoln Pharmaceuticals Ltd (Q2 FY27)
2,798.12 Lakhs increase (approximately 17.1% growth) . Key results statement takeaways from Lincoln Pharmaceuticals Ltd's Q2 FY27 results statement — and how it
Alivus Life Sciences Ltd (Q2 FY27)
Q2 FY27 Revenue from Operations: ₹6,820 million, up 16.0% year-on-year (YoY). Key investor presentation takeaways from Alivus Life Sciences Ltd's Q2 FY27 invest
Strides Pharma Science Ltd (Q2 FY27)
Q2FY27 Revenue: ₹14,297 million, up 17.1% YoY (Page 4, 15) . Key investor presentation takeaways from Strides Pharma Science Ltd's Q2 FY27 investor presentation
Laurus Labs Ltd (Q2 FY27)
2Q FY27 Revenue:** ₹2,206 crore, up 33% year-on-year (Y-o-Y) and 9% quarter-on-quarter (Q-o-Q). Key investor presentation takeaways from Laurus Labs Ltd's Q2 FY

Compare:vs Sun Pharma.Inds.vs Divi's Lab.vs Torrent Pharmaceuticals Ltd

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →